Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual Immunotherapy for Olea europaea Allergic Rhinitis
NCT00537342Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Oct 2007
- Primary completion
- Sep 2009
- Modality
- Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of depigmented polymerized olea europaea pollen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), sponsored by LETI Pharma. Started Oct 2007; status: completed.
02
Drugs
depigmented polymerized olea europaea pollen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT00537342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00537342.